Intracellular Capital Lease Obligations Over Time
| ITCI Stock | USD 86.59 0.16 0.19% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Intracellular Performance and Intracellular Correlation. Intracellular |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.87) | Revenue Per Share 6.096 | Quarterly Revenue Growth 0.39 | Return On Assets (0.07) | Return On Equity (0.1) |
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Capital Lease Obligations Analysis
Compare Intracellular Th and related stocks such as Alkermes Plc, Ironwood Pharmaceuticals, and Deciphera Pharmaceuticals Capital Lease Obligations Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALKS | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 135.2 M | 120.4 M | 105.6 M | 81.5 M | 100.4 M |
| IRWD | 422 K | 422 K | 308 K | 3.1 M | 2.6 M | 306 K | 82 K | 4.1 M | 158 K | 23.2 M | 23.4 M | 21.6 M | 19.7 M | 17.7 M | 9.9 M |
| PCRX | 45.9 M | 45.9 M | 45.9 M | 45.9 M | 45.9 M | 45.9 M | 45.9 M | 45.9 M | 45.9 M | 45.9 M | 78.5 M | 79.6 M | 73.9 M | 63.6 M | 75.1 M |
| COLL | 34 K | 34 K | 34 K | 34 K | 34 K | 34 K | 34 K | 10.1 M | 10.1 M | 10.1 M | 9.5 M | 8.8 M | 8.2 M | 7.1 M | 8 M |
| NBIX | 86.8 M | 86.8 M | 86.8 M | 86.8 M | 86.8 M | 86.8 M | 86.8 M | 86.8 M | 86.8 M | 86.8 M | 94.4 M | 105.3 M | 93.5 M | 258.3 M | 140.4 M |
| DVAX | 37.8 M | 37.8 M | 37.8 M | 37.8 M | 37.8 M | 37.8 M | 37.8 M | 37.8 M | 37.8 M | 37.8 M | 38 M | 34.3 M | 36.4 M | 34.2 M | 28.9 M |
| AMPH | 19.5 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M | 20.8 M | 27.7 M | 26.7 M | 33.6 M | 28.2 M |
| CYTH | 52.5 K | 52.5 K | 52.5 K | 52.5 K | 52.5 K | 52.5 K | 52.5 K | 52.5 K | 52.5 K | 52.5 K | 35.9 K | 19.2 K | 0.0 | 1 M | 1.1 M |
| AMRX | 40.3 M | 40.3 M | 40.3 M | 40.3 M | 40.3 M | 40.3 M | 40.3 M | 40.3 M | 39.3 M | 135.5 M | 123.9 M | 127.4 M | 123.5 M | 109.9 M | 110 M |
| AQST | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 2.8 M | 3.9 M | 5.8 M | 4.4 M |
Intracellular Th and related stocks such as Alkermes Plc, Ironwood Pharmaceuticals, and Deciphera Pharmaceuticals Capital Lease Obligations description
Intracellular Th capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Intracellular asset purchases. For example, Intracellular can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Intracellular control over an asset for a big portion of its life. The total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee.My Equities
My Current Equities and Potential Positions
| Intracellular Th | ITCI |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 86.59
Check out Intracellular Performance and Intracellular Correlation. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Intracellular technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.